IL172510A0 - Antibodies and uses thereof - Google Patents
Antibodies and uses thereofInfo
- Publication number
- IL172510A0 IL172510A0 IL172510A IL17251005A IL172510A0 IL 172510 A0 IL172510 A0 IL 172510A0 IL 172510 A IL172510 A IL 172510A IL 17251005 A IL17251005 A IL 17251005A IL 172510 A0 IL172510 A0 IL 172510A0
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61123803A | 2003-06-30 | 2003-06-30 | |
PCT/US2004/021002 WO2005010153A2 (fr) | 2003-06-30 | 2004-06-30 | Anticorps et utilisations de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
IL172510A0 true IL172510A0 (en) | 2006-04-10 |
Family
ID=34103137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL172510A IL172510A0 (en) | 2003-06-30 | 2005-12-12 | Antibodies and uses thereof |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1649001A2 (fr) |
JP (1) | JP2007528711A (fr) |
KR (1) | KR20060106631A (fr) |
CN (1) | CN101300021A (fr) |
AU (1) | AU2004259406A1 (fr) |
BR (1) | BRPI0411945A (fr) |
CA (1) | CA2536644A1 (fr) |
IL (1) | IL172510A0 (fr) |
MX (1) | MXPA06000252A (fr) |
RU (1) | RU2006102570A (fr) |
WO (1) | WO2005010153A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1714978A1 (fr) * | 2005-04-19 | 2006-10-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Peptides servant au diagnostic et au traitement des tumeurs |
WO2007067983A2 (fr) * | 2005-12-09 | 2007-06-14 | Wyeth | Anticorps specifique de la sulfotyrosine et utilisation a cet effet |
EP2161072A1 (fr) * | 2008-09-03 | 2010-03-10 | Gambro Lundia AB | Membranes d'hémodialyse avec un seuil de coupure pour le traitement de patients nécessitant des hémodialyses régulières |
EP2246364A1 (fr) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anticorps anti CXCR4 pour le traitement du VIH |
EP2371863A1 (fr) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Anticorps humanisé anti CXCR4 pour le traitement du cancer |
RU2663141C2 (ru) * | 2012-01-20 | 2018-08-01 | Джензим Корпорейшн | Анти-cxcr3 антитела |
CN114767858A (zh) * | 2014-07-08 | 2022-07-22 | 桑福德伯纳姆医学研究所 | Psgl-1调控剂及其用途 |
KR20180117102A (ko) * | 2016-01-08 | 2018-10-26 | 바이오얼라이언스 씨.브이. | 사가 항-psgl-1 항체 및 이들의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1458500A (en) * | 1998-10-30 | 2000-05-22 | Jonathan L. Miller | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein IB alpha |
BR0116764A (pt) * | 2000-12-29 | 2007-01-09 | Savient Pharmaceuticals Inc | moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos |
-
2004
- 2004-06-30 MX MXPA06000252A patent/MXPA06000252A/es unknown
- 2004-06-30 BR BRPI0411945-2A patent/BRPI0411945A/pt not_active IP Right Cessation
- 2004-06-30 RU RU2006102570/13A patent/RU2006102570A/ru not_active Application Discontinuation
- 2004-06-30 AU AU2004259406A patent/AU2004259406A1/en not_active Abandoned
- 2004-06-30 KR KR1020057025517A patent/KR20060106631A/ko not_active Application Discontinuation
- 2004-06-30 CA CA002536644A patent/CA2536644A1/fr not_active Abandoned
- 2004-06-30 WO PCT/US2004/021002 patent/WO2005010153A2/fr active Search and Examination
- 2004-06-30 CN CNA2004800249146A patent/CN101300021A/zh active Pending
- 2004-06-30 JP JP2006518730A patent/JP2007528711A/ja active Pending
- 2004-06-30 EP EP04777308A patent/EP1649001A2/fr not_active Ceased
-
2005
- 2005-12-12 IL IL172510A patent/IL172510A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2006102570A (ru) | 2007-08-20 |
JP2007528711A (ja) | 2007-10-18 |
CA2536644A1 (fr) | 2005-02-03 |
BRPI0411945A (pt) | 2006-10-24 |
WO2005010153A2 (fr) | 2005-02-03 |
KR20060106631A (ko) | 2006-10-12 |
WO2005010153A3 (fr) | 2008-03-13 |
AU2004259406A1 (en) | 2005-02-03 |
CN101300021A (zh) | 2008-11-05 |
MXPA06000252A (es) | 2006-12-15 |
EP1649001A2 (fr) | 2006-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL225633A0 (en) | Antibodies against alpha v beta 6 and uses thereof | |
EP1551447A4 (fr) | Anticorps anti-addl et leurs utilisations | |
HK1209759A1 (en) | Ip-10 antibodies and their uses ip-10 | |
IL182554A0 (en) | Anti-addl antibodies and uses thereof | |
IL172871A0 (en) | Rg1 antibodies and uses thereof | |
PT1599504E (pt) | Anticorpo modificado | |
IL175710A0 (en) | Anti-mpl antibody | |
EP1551877A4 (fr) | Anticorps anti-taci et utilisations de ceux-ci | |
ZA200603882B (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | |
IL175491A0 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
EP1494693A4 (fr) | Anticorps specifiques au cripto | |
IL175608A0 (en) | Antibodies | |
ZA200608100B (en) | IRTA-5 antibodies and their uses | |
HK1086284A1 (en) | Kid3 and anti-kid3 antibodies kid3 kid3 | |
EP1699485A4 (fr) | Anticorps anti-hydroxylase et utilisations | |
ZA200703406B (en) | Anti-ADDL antibodies and uses thereof | |
HK1088837A1 (en) | Clk-peptide and slk-peptide | |
IL172510A0 (en) | Antibodies and uses thereof | |
EP1589033A4 (fr) | Anticorps et utilisation de ce dernier | |
IL166063A0 (en) | Antibodies and uses thereof | |
GB0306618D0 (en) | Antibody | |
PL1694845T3 (pl) | Przeciwciała przeciwko rakowi i ich zastosowania | |
EP1627888A4 (fr) | Anticorps et son utilisation | |
ZA200702281B (en) | IRTA-4 antibodies and their uses | |
GB0227080D0 (en) | Antibodies and uses thereof |